Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00024
|
|||||
| Drug Name |
L-glutamine
|
|||||
| Synonyms |
AES-14; Aesgen-14; E-6014; Glutamine (INN); L-glutamine (oral, short bowel syndrome), Emmaus; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus; L-glutamine (oral, sickle cell anemia/sickle beta-0 thalassemia), Emmaus/University of California Los Angeles; L-glutamine (topical, chemotherapy-induced mucositis), Aesgen; NutreStore; Saforis
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Short bowel syndrome [ICD11: KB89.1] | Approved | [1] | |||
| Structure |
|
![]() |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C5H10N2O3
|
|||||
| Canonical SMILES |
C(CC(=O)N)C(C(=O)O)N
|
|||||
| InChI |
InChI=1S/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m0/s1
|
|||||
| InChIKey |
ZDXPYRJPNDTMRX-VKHMYHEASA-N
|
|||||
| CAS Number |
CAS 56-85-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 146.14 | Topological Polar Surface Area | 106 | ||
| Heavy Atom Count | 10 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
-3.1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10527678
, 11341651
, 11361834
, 11363005
, 11365567
, 11368129
, 11372411
, 11375176
, 11376291
, 11485070
, 11487236
, 11489193
, 11491231
, 11493523
, 11493945
, 11537712
, 14710661
, 14719601
, 15297396
, 17405112
, 24277983
, 24872884
, 24895088
, 24895232
, 24895254
, 24895310
, 24895342
, 26612133
, 26679268
, 26747519
, 29224984
, 3133338
, 3364
, 46393493
, 46505866
, 46508385
, 47291275
, 47365367
, 47810918
, 48416059
, 49737762
, 584498
, 6436322
, 7847083
, 7887912
, 8143908
, 8153704
, 828106
, 836113
, 841114
|
|||||
| ChEBI ID |
ChEBI:18050
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | ASCT2 | Transporter Info | Alanine/serine/cysteine/threonine transporter 2 | Substrate | [2] | |
| LAT1 | Transporter Info | L-type amino acid transporter 1 | Substrate | [3] | ||
| SNAT1 | Transporter Info | Sodium-coupled neutral amino acid transporter 1 | Substrate | [4] | ||
| SNAT2 | Transporter Info | Sodium-coupled neutral amino acid transporter 2 | Substrate | [4] | ||
| SNAT3 | Transporter Info | Sodium-coupled neutral amino acid transporter 3 | Substrate | [4] | ||
| SNAT4 | Transporter Info | Sodium-coupled neutral amino acid transporter 4 | Substrate | [4] | ||
| SNAT5 | Transporter Info | Sodium-coupled neutral amino acid transporter 5 | Substrate | [4] | ||
| SNAT7 | Transporter Info | Putative sodium-coupled neutral amino acid transporter 7 | Substrate | [4] | ||
| References | ||||||
| 1 | L-glutamine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes. Neurochem Int. 2006 May-Jun;48(6-7):611-5. | |||||
| 3 | Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009 Feb 6;136(3):521-34. | |||||
| 4 | Identification of SLC38A7 (SNAT7) protein as a glutamine transporter expressed in neurons. J Biol Chem. 2011 Jun 10;286(23):20500-11. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
